The Journal of Pediatrics of Korean Medicine (대한한방소아과학회지)

The Association of Korean Oriental Pediatrics (대한한방소아과학회)
권호 표지
DOI QR코드

DOI QR Code

Genistein Recovers Dermatitis Damage through Endocannabinoid System (ECS) Activity

Genistein의 Endocannabinoid system (ECS) 활성 유도를 통한 피부염 손상 회복 효과

  • Ahn, Sang Hyun (Dept. of anatomy, college of Korean Medicine, Semyung University) ;
  • Seo, Il Bok (Dept. of anatomy, college of Korean Medicine, Semyung University) ;
  • Kim, Ki Bong (School of Korean Medicine, Pusan National University)
  • 안상현 (세명대학교 한의과대학 해부학교실) ;
  • 서일복 (세명대학교 한의과대학 해부학교실) ;
  • 김기봉 (부산대학교 한의학전문대학원 한방소아과학교실)
  • Received : 2020.01.16
  • Accepted : 2020.02.11
  • Published : 2020.02.29
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives After inducing dermatitis in 6-week-old mice, we tried to find out the effects of recovery in the damaged skin by administering genistein and palmitoylethanolamide (PEA) Methods The 6-week-old mice were divided into the control group (Ctrl), dermatitis causing group (AcDE), genistein-administered group after the onset of dermatitis (GsT), and PEA-administered group after the onset of dermatitis (PEAT). Seven mice were assigned to each group. Changes in the skin barrier were observed after three days of administration following the onset of dermatitis. Results In the GsT and PEAT, there was less skin damage compared to the AcDE, and the lowest skin damage showed in the GsT. The intensity of CB1 and CB2 expression was increased by 64% (CB1) and 39% (CB2) in the GsT, and 38% (CB1) and 28% (CB2) in the PEAT compared to the AcDE. The E-catherin positive reaction was decreased in the AcDE, while the E-catherin positive reaction was increased in the GsT (76%) and PEAT (34%). The p-JNK positive reaction was increased in the AcDE, while the p-JNK positive reaction was decreased in the GsT (60%) and PEAT (39%). Toxic Hepatopathy was not observed in the liver tissue of Genistein administered 3OGsT, and PEA administered 3OPEAT. Conclusions Genistein has recovery effect on dermatitis damage through active induction of the endocannabin system (ECS).

Keywords

References

  1. W. Peng, N. Novak. Pathogenesis of atopic dermatitis. Clin Exp Allergy. 2015;45(3):pp.566-74. https://doi.org/10.1111/cea.12495
  2. K. Kabashima. New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity. J Dermatol Sci. 2013:70(1):pp.3-11. https://doi.org/10.1016/j.jdermsci.2013.02.001
  3. P.M. Elias, L.C. Wood, K.R. Feingold. Epidermal pathogenesis of inflammatory dermatoses. Am J Contact Dermat. 1999:10(3);pp.119-26. https://doi.org/10.1016/S1046-199X(99)90054-4
  4. H.Y. Lee. Improvement of skin barrier dysfunction by Scutellaria baicalensis GEOGI extracts through lactic acid fermentation. J Cosmet Dermatol. 2019;18(1):pp.183-91. https://doi.org/10.1111/jocd.12521
  5. G. Imokawa, A. Abe, K. Jin, Y. Higaki, M. Kawashima, A. Hidano. Decreased Level of Ceramides in Stratum Corneum of Atopic Dermatitis: An Etiologic Factor in Atopic Dry Skin?. J Invest Dermatol. 1991;96(4):pp.523-6. https://doi.org/10.1111/1523-1747.ep12470233
  6. J. Manzanares, M. Julian, A. Carrascosa. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol. 2006;4(3):pp.239-57. https://doi.org/10.2174/157015906778019527
  7. P. Pacher, S. Batkai, G. Kunos. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3);pp.389-462. https://doi.org/10.1124/pr.58.3.2
  8. L.K. Miller, L.A. Devi. The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacol Rev. 2011;63(3):pp.461-70. https://doi.org/10.1124/pr.110.003491
  9. T.A. Luger. Neuromediators--a crucial component of the skin immune system. J Dermatol Sci. 2002;30(2):pp.87-93. https://doi.org/10.1016/S0923-1811(02)00103-2
  10. M. Maccarrone, M. Di Rienzo, N. Battista, V. Gasperi, P. Guerrieri, A. Rossi, A. Finazzi-Agro. The Endocannabinoid System in Human Keratinocytes: Evidence that anandamide inhibits epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase. J Biol Chem. 2003;278(36):pp.33896-903. https://doi.org/10.1074/jbc.M303994200
  11. M. Karsak, E. Gaffal, R. Date, L. Wang-Eckhardt, J. Rehnelt, S. Petrosino. Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System. Science. 2007;316(5830):pp.1494-97. https://doi.org/10.1126/science.1142265
  12. M.L. Casanova, C. Blazquez, J. Martinez-Palacio, C. Villanueva, M.J. Fernandez-Acenero, J.W. Huffman, J.L. Jorcano, M. Guzman. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest. 2003;111(1):pp.43-50. https://doi.org/10.1172/JCI200316116
  13. E. Gaffal, M. Cron, N. Glodde, T. Bald, R. Kuner, A. Zimmer, B. Lutz, T. Tuting. Cannabinoid 1 receptors in keratinocytes modulate proinflammatory chemokine secretion and attenuate contact allergic inflammation. J Immunol. 2013;190(10):pp.4929-36. https://doi.org/10.4049/jimmunol.1201777
  14. B.K. Srivastava, R. Soni, JZ. Patel, A. Joharapurkar, N. Sadhwani, S. Kshirsagar, B. Mishra. V. Takale, S. Gupta, P. Pandya, P. Kapadnis, M. Solanki, H. Patel, P. Mitra, M. R. Jain, P.R. Patel. Hair growth stimulator property of thienyl substituted pyrazole carboxamide derivatives as a CB1 receptor antagonist with in vivo antiobesity effect. Bioorg Med Chem Lett. 2009;19(9):pp.2546-50. https://doi.org/10.1016/j.bmcl.2009.03.046
  15. N. Dobrosi, B.I. Toth, G. Nagy, A. Dozsa, T. Geczy, L. Nagy, C.C. Zouboulis, R. Paus, L. Kovacs, T. Biro. Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor-2-mediated signaling. FASEB J. 2008;22(10):pp.3685-95. https://doi.org/10.1096/fj.07-104877
  16. J.M. Walker, A.G. Hohmann. Cannabinoid mechanisms of pain suppression. Handb Exp Pharmacol. 2005;168:pp.509-54. https://doi.org/10.1007/3-540-26573-2_17
  17. M.D. Jhaveri, D. Richardson, V. Chapman. Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol. 2007;152(5):pp.624-32. https://doi.org/10.1038/sj.bjp.0707433
  18. B.I. Toth, N. Dobrosi, A. Dajnoki, G. Czifra, A. Olah, A.G. Szollosi, I. Juhasz, K. Sugawara, R. Paus, T. Biro. Endocannabinoids Modulate Human Epidermal Keratinocyte Proliferation and Survival via the Sequential Engagement of Cannabinoid Receptor-1 and Transient Receptor Potential Vanilloid-1. J Invest Dermatol. 2011;131(5):pp.1095-104. https://doi.org/10.1038/jid.2010.421
  19. K.F. Toth, D. Adam, T. Biro, A. Olah. Cannabinoid Signaling in the Skin: Therapeutic Potential of the "C(ut)annabinoid" System. Molecules. 2019;24(5):pp.918. https://doi.org/10.3390/molecules24050918
  20. S. Li, Z.Q. Zhang, L.J. Wu, X.G. Zhang, Y.D. Li, Y.Y. Wang. Understanding ZHENG in traditional Chinese medicine in the context of neuro-endocrine-immune network. IET Syst Biol. 2007;1(1):pp.51-60. https://doi.org/10.1049/iet-syb:20060032
  21. R.A. Muluye, Y. Bian, P.N. Alemu. Anti-inflammatory and Antimicrobial Effects of Heat-Clearing Chinese Herbs: A Current Review. J Tradit Complement Med. 2014;4(2):pp.93-98. https://doi.org/10.4103/2225-4110.126635
  22. P.S. Qinghu He, Yanhong Zhang. TCM Case Studies: External Medicine. 1st edition, Beijing, PEOPLE'S MEDICAL PUBLISHING HOUSE, 2014.
  23. A.R. Jung, S.H. Ahn, I.S. Park, S.Y. Park, S.I. Jeong, J.H. Cheon, K. Kim. Douchi (fermented Glycine max Merr.) alleviates atopic dermatitis-like skin lesions in NC/Nga mice by regulation of PKC and IL-4. BMC Complement Altern Med. 2016;16:Article No.416.
  24. H.Y. Cha, S.H. Ahn, J.H. Cheon, I.S. Park, J.T. Kim, K. Kim. Hataedock Treatment Has Preventive Therapeutic Effects in Atopic Dermatitis-Induced NC/Nga Mice under High-Fat Diet Conditions. Evid Based Complement Alternat Med. 2016;2016:1739760.
  25. H.Y. Kim, S.H. Ahn, I.J. Yang, K. Kim. Effect of Skin Lipid Barrier Formation on Hataedock Treatment with Douchi. J Korean Med. 2017;38(2):pp.41-52. https://doi.org/10.13048/jkm.17016
  26. J.H. Song, S.H. Ahn, J.H. Cheon, S.Y. Park, H.H. Kim, K. Kim. Effects of Hataedock with Douchi on 2,4-dinitrofluorobenzene-induced Atopic Dermatitislike Skin Lesion in NC/Nga Mice. J Physiol & Pathol Korean Med. 2016;30(2):pp.109-15. https://doi.org/10.15188/kjopp.2016.04.30.2.109
  27. J.M. McPartland, G.W. Guy, V. Di Marzo. Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system. PloS one. 2014;9(3):e89566. https://doi.org/10.1371/journal.pone.0089566
  28. V. Di Marzo. New approaches and challenges to targeting the endocannabinoid system. Nat Rev Drug Discov. 2018;17(9):pp.623-39. https://doi.org/10.1038/nrd.2018.115
  29. A. Dizamatova, K. Zhumanova, G.E. Zhusupova, A.I. Zhussupova, R. Srivedavyasasri, M.A. Ibrahim, S.A. Ross. A New Prenylated Isoflavonoid From Limonium leptophyllum. Nat Prod Commun. 2019;14(5):1934578X19844137.
  30. L. Thors, J.J. Burston, B.J. Alter, M.K. Mckinney, B.F. Cravatt, R.A. Ross, R.G. Pertwee, R.W. Gereau, J.L. Wiley, C.J. Fowler. Biochanin A, a naturally occurring inhibitor of fatty acid amide hydrolase. Br J Pharmacol. 2010;160(3):pp.549-60. https://doi.org/10.1111/j.1476-5381.2010.00716.x
  31. K. Natsuga. Epidermal barriers. Cold Spring Harb Perspect Med. 2014;4(4):a018218. https://doi.org/10.1101/cshperspect.a018218
  32. C. Blanpain, E. Fuchs. Epidermal homeostasis: a balancing act of stem cells in the skin. Nat Rev Mol Cell Biol. 2009;10(3):pp.207-17. https://doi.org/10.1038/nrm2636
  33. J.K. Kim, J.H. Lee, I.H. Bae, D.B. Seo, S.J. Lee. Beneficial Effect of a Collagen Peptide Supplement on the Epidermal Skin Barrier. Korean J Food Sci Tech. 2011;43(4):pp.458-63. https://doi.org/10.9721/KJFST.2011.43.4.458
  34. Kim BB, Kim JR, Kim JH, Kim YA, Park JS, Yeom MH, Lee HJ, Lee KW, Kang NJ. 7, 3', 4'-Trihydroxyisoflavone ameliorates the development of Dermatophagoides farinae-induced Atopic Dermatitis in NC/Nga Mice. Evid Based Complement Alternat Med. 2013;2013:636597
  35. Irvine AD, McLean WH. Breaking the (un)sound barrier: filaggrin is a major gene for atopic dermatitis. J Invest Dermatol. 2006;126:1200-02. https://doi.org/10.1038/sj.jid.5700365
  36. C.N. Palmer, A.D. Irvine, A. Terron-Kwiatkowski, Y. Zhao, H. Liao, S.P. Lee, D.R. Goudie, A. Sandilands, L.E. Campbell, F.J. Smith, G.M. O'Regan, R.M. Watson, J.E. Cecil, S.J. Bale, J.G. Compton, J.J. DiGiovanna, P. Fleckman, S. Lewis-Jones, G. Arseculeratne, A. Sergeant, C.S. Munro, B.E. Houate, K. McElreavey, L.B. Halkjaer, H. Bisgaard, S. Mukhopadhyay, W.H. McLean. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38:441-6. https://doi.org/10.1038/ng1767
  37. O'Regan GM, Irvine AD. The role of filaggrin in the atopic diathesis. Clin Exp Allergy. 2010;40:965-72. https://doi.org/10.1111/j.1365-2222.2010.03522.x
  38. Barnes KC. An update on the genetics of atopic dermatitis: scratching the surface in 2009. J Allergy Clin Immunol. 2010;125(1):16-29. https://doi.org/10.1016/j.jaci.2009.11.008
  39. P. Kupczyk, A. Reich, J.C. Szepietowski. Cannabinoid system in the skin - a possible target for future therapies in dermatology. Exp Dermatol. 2009;18(8):pp.669-79. https://doi.org/10.1111/j.1600-0625.2009.00923.x
  40. M. Salzet. Invertebrate molecular neuroimmune processes. Brain Res Rev, 2000;34(1):pp.69-79. https://doi.org/10.1016/S0165-0173(00)00041-2
  41. H. Yang, J. Zhou, C. Lehmann. GPR55 - a putative "type 3" cannabinoid receptor in inflammation. J Basic Clin Physiol Pharmacol. 2016;27(3):pp.297-302. https://doi.org/10.1515/jbcpp-2015-0080
  42. G. Nam, S.K. Jeong, B.M. Park, S.H. Lee, H.J. Kim, S.P. Hong, B. Kim, B.W. Kim. Selective Cannabinoid Receptor-1 Agonists Regulate Mast Cell Activation in an Oxazolone-Induced Atopic Dermatitis Model. Ann Dermatol, 2016;28(1):pp.22-9. https://doi.org/10.5021/ad.2016.28.1.22
  43. H.J. Kim, B. Kim, B.M. Park, J.E. Jeon, S.H. Lee, S. Mann, S.K. Ahn, S.P. Hong, S.K. Jeong. Topical cannabinoid receptor 1 agonist attenuates the cutaneous inflammatory responses in oxazolone-induced atopic dermatitis model. Int J Dermatol. 2015;54(10):pp.401-8.
  44. T. Haruna, M. Soga, Y. Morioka, K. Imura, Y. Furue, M. Yamamoto, J. Hayakawa, M. Deguchi, A. Arimura, K. Yasui. The Inhibitory Effect of S-777469, a Cannabinoid Type 2 Receptor Agonist, on Skin Inflammation in Mice. Pharmacology. 2017;99(5-6):pp.259-67. https://doi.org/10.1159/000455916
  45. G. Cantarella, M. Scollo, L. Lempereur, G. Saccani-Jotti, F. Basile, R. Bernardini. Endocannabinoids inhibit release of nerve growth factor by inflammation-activated mast cells. Biochem Pharmacol. 2011;82(4):pp.380-8. https://doi.org/10.1016/j.bcp.2011.05.004
  46. J.P. Thiery, J.P. Sleeman. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):pp.131-42. https://doi.org/10.1038/nrm1835
  47. P.F. Cheung, C.K. Wong, A.W Ho, S. Hu, D.P. Chen, C.W. Lam. Activation of human eosinophils and epidermal keratinocytes by Th2 cytokine IL-31: implication for the immunopathogenesis of atopic dermatitis. Int Immunol. 2010;22(6):pp.453-67. https://doi.org/10.1093/intimm/dxq027
  48. S. Arbabi, R.V. Maier. Mitogen-activated protein kinases. Crit Care Med. 2002;30(1) Suppl:pp.s74-9. https://doi.org/10.1097/00003246-200201001-00010
  49. Q. Tan, H. Yang, E. Liu, H. Wang. P38/ERK MAPK signaling pathways are involved in the regulation of filaggrin and involucrin by IL-17. Mol Med Rep. 2017;16(6):pp.8863-67. https://doi.org/10.3892/mmr.2017.7689